ArticleOpen forum infectious diseases2026
Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A previous RESPOND analysis suggested that integrase inhibitors (INSTIs) increase cardiovascular disease (CVD) risk compared with other antiretroviral therapy (ART). We reanalyzed the data using target trial emulations examining the impact of methodological choices. Methods: Treatment-naïve analyses included ART-naïve adults with detectable HIV viraemia and recent CD4 and HIV-RNA measurements. Treatment-experienced analyses included adults with suppressed HIV-RNA receiving INSTI-free ART. We estimated adjusted risk differences (RDs) and risk ratios (RRs) for CVD events comparing INSTI initiation or switching versus other ART using inverse-probability weighting and pooled logistic regression. Results: Among 7111 treatment-naïve individuals, 95 CVD events occurred over a median of 62 months. Risk ratios comparing INSTI initiation with starting other ART were 1.07 (95% confidence interval .29-4.93) at 1 year, 1.21 (.41-3.91) at 2 years, and 1.87 (1.06-3.26) at 6 years. Corresponding RDs were 0.02% (-.32-.29), 0.09% (-.43-.53), and 1.03% (0.08-2.07). Among 22 921 treatment-experienced individuals, 800 CVD events occurred over a median of 37 months. Risk ratios were 1.55 (1.16-2.00) at 1 year, 1.30 (1.07-1.62) at 2 years, and 0.93 (.78-1.09) at 6 years. Corresponding RDs were 0.26% (.08-.47), 0.29% (.03-.58), and -0.22 (-.66-.25). Conclusions: Switching to INSTIs was associated with a transient increase in CVD risk during the first 2 years among treatment-experienced individuals, whereas starting INSTIs in ART-naïve individuals was associated with a gradual increase over time, albeit based on few events. Absolute RDs remained small, but the findings suggest a potential impact of INSTIs on the development of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.